When COVID-19 emerged in early 2020, the Global Fund took swift action to fight the pandemic and protect hard-won gains against HIV, tuberculosis (TB), and malaria. With the support of our generous donors, we have since awarded more than US$4.4 billion to help countries respond to the new virus, mitigate its impact on lifesaving HIV, TB and malaria services and make urgent improvements to health systems. While we were not able to prevent COVID-19 from having a massive impact on people living in low- and middle-income countries, including both the direct impact of the new virus and the reversal of hard-won gains against HIV, TB, and malaria, it could have been much worse.
We saw the benefits of the interventions we made in 2021, with gains in key programmatic results across all three diseases. The Global Fund’s Results Report 2022 details how our partnership played a critical role in supporting countries and communities to respond to the pandemic and continue the progress in the fight against HIV, TB, and malaria.
Key Results and Lives Saved
Health programs supported by the Global Fund partnership had saved 50 million lives as of the end of 2021.
The coverage of treatment and prevention interventions for HIV, TB, and malaria in countries where the Global Fund invests has increased rapidly since we were created in 2002. However, while the growth in HIV coverage levels remains steady, TB and malaria coverage have both declined in recent years. Declines in TB coverage are mostly due to disruptions caused by the COVID-19 pandemic, and declines in malaria coverage in sub-Saharan Africa may partly reflect better targeting of mosquito nets. The Global Fund is investing to get the world back on track toward ending AIDS, TB, and malaria, building resilient and sustainable systems for health and strengthening pandemic preparedness, making the world more equitable and safer from future threats.
The Global Fund galvanizes the world to invest in the fight against the deadliest infectious diseases while challenging the injustice that continues to fuel them. Our work unites world leaders, communities, civil society, health workers and the private sector to create solutions and take them to scale.2022 Report
We measure our progress against the targets in the global plans for HIV, TB, and malaria and in the Sustainable Development Goal 3 of health and well-being for all. Our achievement is the result of efforts by a wide array of actors comprising the Global Fund partnership, including governments, multilateral agencies, bilateral partners, civil society groups, people affected by the diseases, and the private sector.
Together with the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) and other partners, our efforts to implement WHO’s “treat all” guidance and the UNAIDS “95-95-95” strategy have significantly increased the number of people diagnosed with HIV and started on antiretroviral therapy. In 2021, in countries where the Global Fund invests, HIV testing services for groups in greatest need started to recover. 23.3 million people were receiving lifesaving antiretroviral therapy, up from 21.9 million in 2020. The percentage of people in need of antiretroviral therapy who received it has significantly increased over the past decade, from 23% in 2010 to 75% in 2021.